EUVIMEDEUVIMED entdecken
Crossref

Initiation of Haploidentical Stem Cell Transplantation With Post‐Transplant Cyclophosphamide in Children: A Low–Middle‐Income Country Institutional Experience

Syed Ibrahim Bukhari iD, Javeria Saeed, Zehra Fadoo, Asim Fakhruddin Belgaumi, Naureen Allani, Sadaf Altaf

Pediatric Transplantation · 2024

DOI: 10.1111/petr.14842 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Transplantation, 2024. Verfasst von Syed Ibrahim Bukhari und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Aga Khan University, Karachi, Pakistan. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Transplantation, Haploidentical, Cyclophosphamide, Immunosuppressive Agents. Die Arbeit nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Haploidentical hematopoietic stem cell transplant (HSCT) is a curative treatment especially for countries where bone marrow registries are nonexistent. We present our experience with haploidentical HSCT in pediatric patients.

Methods

Retrospective data collected and analyzed for patients ≤18 years, from January 2017 to December 2022.

Results

The cohort consisted of 20 patients with median age at transplant of 61.5 (IQR: 124) months. Fourteen (70%) were malignant and 6 (30%) were benign diseases. Donors were father in majority (9/20; 45%). Stem cell source was peripheral blood 8, marrow 8, and combined 4. c‐specific antibodies were positive in 6 (30%). Median CD34 cell dose infused: 9.35 × 10 6 /kg. Median engraftment time: 15 (IQR: 17) days. Acute and chronic graft‐versus‐host disease (GVHD) occurred in 12/20 (60%) and 5/20 (25%), respectively. Complications included infection/sepsis (14/20; 70%), cytomegalovirus reactivation (14/20; 70%), sinusoidal obstruction syndrome (1/20; 5%), primary graft failure (PGF) (6/20; 30%), and secondary graft failure (4/20; 20%). PGF was more common in benign conditions ( p = 0.003) and less prevalent in cases with aGVHD ( p = 0.007). aGVHD was more common in malignant conditions ( p = 0.007). Overall survival (OS), relapse‐free survival (RFS), and treatment‐related mortality (TRM) were 40%, 50%, and 35%, respectively. Median time of survival and relapse were 8 (IQR: 15) and 9 (IQR: 13) months, respectively.

Conclusion

OS was comparable to that of other low–middle‐income countries. GVHD was a major challenge, along with sepsis and CMV infection. Half of the leukemias relapsed. Graft failure was a major concern in nonmalignant diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationTransplantation, HaploidenticalCyclophosphamideImmunosuppressive AgentsHumansRetrospective StudiesMaleFemaleChildChild, PreschoolInfantAdolescentGraft vs Host DiseaseDeveloping Countries

Stichwörter der Autor:innen

conditioning regimengraft rejectiongraft‐versus‐host diseasestem cell transplantationtransplant‐related toxicity

Substanzen

CyclophosphamideImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Oncology, Aga Khan University, Karachi, Pakistan.
  • Department of Surgery, Aga Khan University, Karachi, Pakistan.

ORCID-Profile: Syed Ibrahim Bukhari

Zitieren

APA

Bukhari, S. I., Saeed, J., Fadoo, Z., Belgaumi, A. F., Allani, N., & Altaf, S. (2024). Initiation of Haploidentical Stem Cell Transplantation With Post‐Transplant Cyclophosphamide in Children: A Low–Middle‐Income Country Institutional Experience. Pediatric Transplantation. https://doi.org/10.1111/petr.14842

Vancouver

Bukhari SI, Saeed J, Fadoo Z, Belgaumi AF, Allani N, Altaf S. Initiation of Haploidentical Stem Cell Transplantation With Post‐Transplant Cyclophosphamide in Children: A Low–Middle‐Income Country Institutional Experience. Pediatric Transplantation. 2024. doi:10.1111/petr.14842

BibTeX
@article{Bukhari2024,
  author = {Bukhari, Syed Ibrahim and Saeed, Javeria and Fadoo, Zehra and Belgaumi, Asim Fakhruddin and Allani, Naureen and Altaf, Sadaf},
  title = {Initiation of Haploidentical Stem Cell Transplantation With Post‐Transplant Cyclophosphamide in Children: A Low–Middle‐Income Country Institutional Experience},
  journal = {Pediatric Transplantation},
  year = {2024},
  doi = {10.1111/petr.14842}
}
Kostenlos starten →